Navigation Links
Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting
Date:11/7/2011

, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward-Looking Statements
This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, the expanded access program, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the submission, review, potential approval of the NDA, development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(1) National Cancer Institute, Surveillance Epidemiology and End Results, 2007 Facts and Figures
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
2. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
3. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
4. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
6. Quanticel Pharmaceuticals Enters Into Strategic Cancer Drug Discovery Collaboration With Celgene Corporation
7. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
10. Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... , September 17, 2014 According ... by Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), ... & Wellness), and by Geography - Global Forecast to ... electronics market is expected to reach $56.50 Billion by ... to 2020. Browse 235 market data Tables ...
(Date:9/17/2014)... CITY, Utah , Sept. 17, 2014 /PRNewswire/ ... an exclusive global licensing and collaboration agreement with ... and commercialize NuView,s investigative genomic-based diagnostic biomarker to ... agreement also includes all other future diagnostic-imaging applications. ... for in-vivo therapeutic delivery and in-vitro urine screen ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
... WORCESTER, Mass. and TORONTO, May 17, 2012  Generex ... today that new members have joined the Scientific ... Express, Inc. for the company,s AE37 breast cancer ... N. Hortobagyi, MD, FACP (University of Texas MD ...
... TUCSON, Ariz., May 17, 2012 SynCardia Systems, Inc. ... only FDA, Health Canada and CE (Europe) approved Total ... March 31, 2012, due in part to Certified Centers ... SynCardia temporary Total Artificial Heart . ...
Cached Medicine Technology:Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 2Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 3Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine 4SynCardia Posts Record Revenue and Profit in Q1 2012 2SynCardia Posts Record Revenue and Profit in Q1 2012 3
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Present-day ... groups of ancient humans, according to a new ... descended from indigenous hunter-gatherers and early European farmers. ... samples revealed they are also the descendants of ... genetic material from this third ancestral group, researchers ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... Diabetics and dieters who turn to artificial sweeteners to ... any favors, a new Israeli study suggests. Artificial ... containing no calories, researchers found in human and mouse ... to alter the bacteria residing in the intestines in ...
(Date:9/17/2014)... Research has shown that most 18-month-olds learn an ... however, little is known about how children process information ... preschool years. In a new study, a University of ... as they age, and a limit exists as to ... findings could help parents enhance their children,s vocabularies and ...
(Date:9/17/2014)... In a country where 77% of ... regular basis, how can Americans find healthy and fulfilling ... Stress Challenge , a 5-day interactive journey to putting ... From September 29th – October 3rd, the Hyland’s ... to specific topics that promote natural solutions for managing ...
(Date:9/17/2014)... Doheny HealthDay Reporter WEDNESDAY, ... beverage companies have made good on their pledge to cut ... The companies, acting together through the Healthy Weight Commitment Foundation, ... 2007 and 2012 and 1.5 trillion by 2015. They,ve actually ... collectively met their pledge and exceeded their pledge," said lead ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3Health News:Babies learn words differently as they age, researcher finds 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... in patients aged 80 and older, researchers say , ... questions the widespread use of implantable cardiac devices in ... in the hospital after receiving the devices. , Patients ... implantable defibrillators and pacemakers, even though most clinical trials ...
... no longer safe on the road , MONDAY, April ... input from family members are the most useful tools in ... or other dementia sets in, according to new guidelines from ... assessments are usually more accurate than the patient,s own opinion ...
... expert says , MONDAY, April 12 (HealthDay News) -- A ... in the blood raises the risk of heart disease for ... however, is not seen in men, according to the report, ... . , The study, by researchers at Italy,s National Cancer ...
... Important advances in the fight against cancer have come as ... were previously unknown to scientists. A new study led ... activate a viral infection that, paradoxically, can help anti-viral medications ... a team of UNC School of Medicine scientists and the ...
... In an ongoing effort to scientifically validate the age-old belief ... of patients, The University of Texas M. D. Anderson Cancer ... the efficacy of incorporating yoga into the treatment program of ... ever awarded by the National Cancer Institute for the study ...
... pain can go on too long and be ineffective, study ... that many patients with terminal cancer don,t benefit from getting ... symptoms like pain. , The researchers, who reported their findings ... Cancer , say doctors are failing to properly adjust treatments ...
Cached Medicine News:Health News:Study Questions Use of Heart Device Implants in the Very Old 2Health News:Docs Issue Guidelines for Drivers With Dementia 2Health News:Docs Issue Guidelines for Drivers With Dementia 3Health News:Simple Carbs Pose Heart Risk for Women 2Health News:Simple Carbs Pose Heart Risk for Women 3Health News:UNC study offers first clinical evidence of anti-cancer drug triggering viral infection 2Health News:M. D. Anderson receives 4.5 million grant, largest ever for study of yoga and cancer 2Health News:Many Terminal Cancer Patients May Be Overtreated 2
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Detection of Malarial antigen in Human whole blood....
The KAT-Quick Malaria test was designed for the diagnosis of Malaria, in laboratories, the home and for medical kits when travelling into malaria regions....
Medicine Products: